Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$1.17 - $1.94 $362 - $601
-310 Reduced 0.86%
35,933 $52,000
Q4 2023

Feb 13, 2024

SELL
$1.02 - $1.47 $148 - $214
-146 Reduced 0.4%
36,243 $46,000
Q3 2023

Nov 13, 2023

BUY
$0.93 - $1.38 $1,203 - $1,785
1,294 Added 3.69%
36,389 $44,000
Q2 2023

Aug 04, 2023

BUY
$1.11 - $2.05 $38,955 - $71,944
35,095 New
35,095 $43,000
Q2 2021

Aug 13, 2021

SELL
$2.91 - $3.83 $59,279 - $78,020
-20,371 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$3.47 - $4.75 $183 - $251
53 Added 0.26%
20,371 $75,000
Q4 2020

Feb 12, 2021

SELL
$3.2 - $4.98 $1,862 - $2,898
-582 Reduced 2.78%
20,318 $84,000
Q3 2020

Nov 04, 2020

BUY
$3.69 - $7.09 $7,479 - $14,371
2,027 Added 10.74%
20,900 $82,000
Q2 2020

Aug 12, 2020

BUY
$3.58 - $7.44 $8,889 - $18,473
2,483 Added 15.15%
18,873 $140,000
Q1 2020

May 04, 2020

BUY
$3.49 - $9.2 $2,739 - $7,221
785 Added 5.03%
16,390 $74,000
Q4 2019

Feb 05, 2020

SELL
$6.27 - $11.41 $827 - $1,506
-132 Reduced 0.84%
15,605 $144,000
Q3 2019

Nov 08, 2019

SELL
$4.75 - $8.38 $517 - $913
-109 Reduced 0.69%
15,737 $110,000
Q2 2019

Aug 13, 2019

BUY
$6.4 - $10.94 $23,084 - $39,460
3,607 Added 29.47%
15,846 $112,000
Q1 2019

May 06, 2019

SELL
$6.1 - $10.3 $2,421 - $4,089
-397 Reduced 3.14%
12,239 $126,000
Q4 2018

Feb 13, 2019

SELL
$5.84 - $11.92 $566 - $1,156
-97 Reduced 0.76%
12,636 $78,000
Q3 2018

Nov 09, 2018

BUY
$12.43 - $29.76 $27,992 - $67,019
2,252 Added 21.49%
12,733 $158,000
Q2 2018

Aug 08, 2018

BUY
$18.75 - $28.46 $131,418 - $199,476
7,009 Added 201.87%
10,481 $293,000
Q1 2018

May 07, 2018

SELL
$15.91 - $20.82 $2,959 - $3,872
-186 Reduced 5.08%
3,472 $70,000
Q4 2017

Feb 09, 2018

BUY
$15.2 - $20.76 $55,601 - $75,940
3,658
3,658 $69,000

Others Institutions Holding OPTN

About OptiNose, Inc.


  • Ticker OPTN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 83,277,504
  • Market Cap $42.5M
  • Description
  • OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...
More about OPTN
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.